1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
The European Commission granted marketing authorization for Ubeslo and Evlarco, obicetrapib-based treatments for primary hypercholesterolaemia or mixed dyslipidaemia, marking the first regulatory approval of obicetrapib worldwide. The company's partner Menarini holds European commercialization rights, and the approvals trigger milestone payments in the mid-teens of millions of euros, with up to an additional €833 million available on future milestones.
Approvals cover all EU Member States, Iceland, Liechtenstein and Norway
Ubeslo is obicetrapib 10 mg monotherapy; Evlarco is 10 mg obicetrapib plus 10 mg ezetimibe
EC requires a post-authorization efficacy study and final results from the PREVAIL cardiovascular outcomes trial
Menarini milestone payments in the mid-teens of millions of euros triggered by the authorizations
Nasdaq notified Linkhome Holdings on September 18, 2026 that the company has regained compliance with the $1.00 minimum bid price requirement, closing the matter. The company had received a deficiency notice on June 29, 2026 after its stock closed below $1.00 for 30 consecutive business days. Shareholders face no listing action from this matter, since the stock met the bid price test for 10 consecutive business days.
Nasdaq deficiency notice received June 29, 2026 after 30 consecutive business days below $1.00
Closing bid price was at least $1.00 for 10 consecutive business days, September 3 through September 17, 2026
Nasdaq notified the company on September 18, 2026 that compliance was regained and the matter is closed
Trilogy Metals said the U.S. Army Corps of Engineers has published a Notice of Intent to prepare an Environmental Impact Statement for its flagship Arctic Project in northwestern Alaska, formally starting the National Environmental Policy Act review and a public scoping phase. The company said the schedule still targets a draft EIS in October 2027 and a Record of Decision in September 2028, which shareholders may watch as the project's main federal permitting milestones.
Notice of Intent published by the U.S. Army Corps of Engineers, announced September 21, 2026, launching public scoping
Schedule continues to target a draft EIS in October 2027 and a Record of Decision in September 2028
Clean Water Act Section 404 permit application was filed by Ambler Metals on April 20, 2026
Arctic Project is advanced by Ambler Metals LLC, a 50/50 joint venture with South32
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.